Synthetic method of bilastine intermediate
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 湖北英纳氏生物科技有限公司
- Publication Date
- 2021-05-11
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of organic synthesis, in particular to a method for synthesizing a bilastine intermediate. Background technique
[0002] Bilastine (Bilst for short), the chemical name is 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzimidazol-2-yl}B base)-phenyl]2-methyl-propionic acid, cas number 202189-78-4. Bilastine is an oral second-generation histamine H1 receptor antagonist developed by Spanish FAES Pharmaceutical Company. It was registered as a new drug in the European Union in 2009, and was first approved for marketing in the UK and Ireland in 2011, and then successively marketed in Italy, Japan, Canada and other countries. It is used for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. The dosage specification is 20mg / piece. Other approved indications include pruritus, eczema and hives. This product is safe, without the sedative effect and cardiotoxicity of commonly used antihistamines. ...